Showing 2721-2730 of 3315 results for "".
- Study Lays Foundation for Establishing Base Editing as a One-Time, Durable Treatment for Inherited Retinal Degenerationhttps://modernod.com/news/study-lays-foundation-for-establishing-base-editing-as-a-one-time-durable-treatment-for-inherited-retinal-degeneration/2480766/A new University of California, Irvine-led study indicates base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis (LCA) patients. “Our findings demo
- ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategyhttps://modernod.com/news/proqr-announces-additional-sepofarsen-illuminate-trial-analyses-and-provides-update-on-company-strategy/2480765/ProQR Therapeutics provided an update on its sepofarsen program following a comprehensive post-hoc analysis of the data from the phase 2/3 Illuminate trial in people with CEP290-mediated Lebercongenital amaurosis 10, or LCA10, a
- Staar Surgical Announces First Implants of EVO Visian ICL in the UShttps://modernod.com/news/staar-surgical-announces-first-implants-of-evo-visian-icl-in-the-us/2480751/Staar Surgical announced the first implants of the EVO Visian Implantable Collamer lens (EVO ICL) in the US. The company also announced its program of meetings and presentations during the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Washington, DC, Apri
- Shamir Group Employees Around the World are Mobilized for Humanitarian Aid for Ukrainian Refugees in Warsawhttps://modernod.com/news/shamir-group-employees-around-the-world-are-mobilized-for-humanitarian-aid-for-ukrainian-refugees-in-warsaw/2480745/Shamir is now voluntarily operating traveling laboratories for testing and fitting of eyeglasses among Ukrainian refugees, located at the Patk Expo complex in Warsaw, Poland. The mobile laboratories on wheels are equipped with advanced technology for rapid production of advanced lenses&mdash
- IAPB Introduces ‘Focus On Child Eye Health’https://modernod.com/news/iapb-introduces-focus-on-child-eye-health/2480729/Over the last few years, The International Agency for the Prevention of Blindness (IAPB) reached the world’s thought leaders with its ‘Focus On Glaucoma’ and ‘Focus On Diabetes’ series. The organization is excited to expand thi
- Innovega Grants Commercial License of its Next-Generation Display Eyewear to Global Supplierhttps://modernod.com/news/innovega-grants-commercial-license-of-its-next-generation-display-eyewear-to-global-supplier/2480728/Innovega finalized a definitive licensing agreement with one of the world's leading providers of assistive technology for the visually impaired, including the legally blind. This is the first commercial licensing agreement for Innovega’s next-generation display eyewear
- Harvard Eye Associates Surgeons Implant the First AccuraSee IOPCL to Treat Macular Degenerationhttps://modernod.com/news/harvard-eye-associates-surgeons-implant-the-first-accurasee-iopcl-to-treat-macular-degeneration/2480721/Harvard Eye Associates reported that its surgeons have implanted the first AccuraSee Intraocular Pseudophakic Contact Lens (IOPCL) to improve near vision in patients with macular degeneration. The AccuraSee lens implant is placed to help magnify images and allow patients to use parts of
- Evmann Creates Roadmap to Facilitate its Development into a €1 Billion Global Companyhttps://modernod.com/news/evmann-creates-roadmap-to-facilitate-its-development-into-a-eur1-billion-global-company/2480714/Dutch Evmann Investments Holding, the parent company of VSY Biotechnology, organized its 2022 Global Leadership Meeting last week in line with its strategic plans to become a "unicorn" company. "Unicorn" is a term used in the venture capital industry to describe 
- Visus Therapeutics Initiates Phase 3 Pivotal Trials of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-initiates-phase-3-pivotal-trials-of-brimochol-pf-for-the-treatment-of-presbyopia/2480710/Visus Therapeutics announced the launch of the first of two pivotal phase 3 trials (BRIO-I and BRIO-II) for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. The initiation of the BRIO trials follows compelling topline data from th
- Horizon Therapeutics and IAPB Partner to Advocate for Better Eye Healthhttps://modernod.com/news/horizon-therapeutics-and-iapb-partner-to-advocate-for-better-eye-health/2480708/The International Agency for the Prevention of Blindness (IAPB) has announced that Horizon Therapeutics has joined IAPB as a Global Patron. Working together, Horizon and IAPB will advocate to bring better eye health to all at global, country and regional levels. Horizon and IAPB w